Robert Hugh Bradbury

This inventor holds 40 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Astrazeneca Ab, Imperial Chemical Industries Limited, Zeneca Limited. Active years: 1991-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Hugh Bradbury. Retrieved from https://idiyas.com/inventor/robert-hugh-bradbury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40 (Patent Applications = 7)

% Patents Active = 72.5

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 2.9

ph-index = 9

Forward Citations = 594(Granted Patents)

Location History:

Wilmslow, GB (1991 - 2001)
Macklesfield, GB (2006)
Macclesfield, GB (1999 - 2018)
Cheshire, GB (1999 - 2020)
Cambridge, GB (2022)

Company Filing History:

Imperial Chemical Industries Limited

where one patent can have more than one assignee

Years Active: 1991-2022

Loading Chart...

Areas of Expertise:

Triazolo Compounds

Quinazoline Derivatives

Heterocyclic Compounds

Antiproliferative Agents

Pyrimidine Compounds

Angiotensin II Antagonists

Sulphonamide Derivatives

Cephalosporin Intermediates

Bicyclic Derivatives

N-heterocyclic Compounds

Pharmaceutical Activity

Anti-cell Proliferative Activity

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11407755 - [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases (2022-08-09),

2. 10766905 - [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases (2020-09-08),

3. 10407432 - [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases (2019-09-10),

4. 10130617 - Chemical compounds (2018-11-20),

5. 9944650 - [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases (2018-04-17),

6. 9616050 - Chemical compounds (2017-04-11),

7. 9155727 - Chemical compounds (2015-10-13),

8. 8399667 - 4-anilino quinazoline derivatives as antiproliferative agents (2013-03-19),

9. 8258140 - Chemical compounds—643 (2012-09-04),

10. 8003649 - Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 (2011-08-23),

11. 7820683 - 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer (2010-10-26),

12. 7625908 - Quinazoline derivatives (2009-12-01),

13. 7148230 - Quinazoline derivatives (2006-12-12),

14. 7067522 - 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents (2006-06-27),

15. 6838464 - 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents (2005-01-04),

Title: The Innovative Contributions of Robert Hugh Bradbury

Introduction: Robert Hugh Bradbury, a prominent inventor based in Macclesfield, GB, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 40 patents, Bradbury's work focuses primarily on compounds that demonstrate anti-proliferative properties, which are essential in treating various proliferative diseases.

Latest Patents: Among his notable inventions are the patented compounds labeled as [1,2,4]triazolo[4,3-b]pyridazines. These compounds are designed for use in the treatment of proliferative diseases. His inventions concern compounds of Formula (I) or pharmaceutically-acceptable salts thereof, where R, R', and n have specific definitions as outlined in the patent description. These compounds can be processed into pharmaceutical compositions that are utilized as anti-proliferative and/or cell-killing agents, showcasing Bradbury's dedication to advancing medical treatments.

Career Highlights: Throughout his career, Robert Hugh Bradbury has worked with several renowned companies, including AstraZeneca and Imperial Chemical Industries Limited. His experiences in these prominent firms have played a crucial role in shaping his innovative capabilities and understanding of pharmaceutical development.

Collaborations: Noteworthy collaborations include working alongside talented individuals such as David A. Roberts and Alfred Arthur Rabow. These partnerships have likely enhanced his inventive processes and contributed to the success of his patented compounds.

Conclusion: Robert Hugh Bradbury stands out as an influential inventor with a commendable track record in pharmaceuticals. His 40 patents reflect a commitment to innovation in the treatment of proliferative diseases, promising advancements in medical science through his groundbreaking work. As the field continues to evolve, the impact of his inventions is sure to resonate within the industry for years to come.

Profile summary based on public USPTO records.